A Case of Evan's Syndrome Induced by Vedolizumab

Vedolizumab is a monoclonal antibody against the ɑ4β7 integrin receptor used for the treatment of ulcerative colitis and Crohn's disease. Clinical trials have shown vedolizumab to be a safe and highly effective therapy in treating inflammatory bowel disease. Its unique gut-specific mechanism of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jen, Henry, Morganstern, Bradley, D'Souza, Lionel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657984/
https://www.ncbi.nlm.nih.gov/pubmed/31598531
http://dx.doi.org/10.14309/crj.0000000000000002
_version_ 1783438887571423232
author Jen, Henry
Morganstern, Bradley
D'Souza, Lionel
author_facet Jen, Henry
Morganstern, Bradley
D'Souza, Lionel
author_sort Jen, Henry
collection PubMed
description Vedolizumab is a monoclonal antibody against the ɑ4β7 integrin receptor used for the treatment of ulcerative colitis and Crohn's disease. Clinical trials have shown vedolizumab to be a safe and highly effective therapy in treating inflammatory bowel disease. Its unique gut-specific mechanism of action has made it an attractive agent in recent years. However, vedolizumab's side effect profile and long-term effects are not fully understood. We report a patient with ulcerative colitis who presented with epistaxis 1 week after receiving the first induction dose of vedolizumab found to have a severe immune-mediated thrombocytopenia and hemolytic anemia, otherwise known as Evan's syndrome.
format Online
Article
Text
id pubmed-6657984
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-66579842019-10-09 A Case of Evan's Syndrome Induced by Vedolizumab Jen, Henry Morganstern, Bradley D'Souza, Lionel ACG Case Rep J Case Report Vedolizumab is a monoclonal antibody against the ɑ4β7 integrin receptor used for the treatment of ulcerative colitis and Crohn's disease. Clinical trials have shown vedolizumab to be a safe and highly effective therapy in treating inflammatory bowel disease. Its unique gut-specific mechanism of action has made it an attractive agent in recent years. However, vedolizumab's side effect profile and long-term effects are not fully understood. We report a patient with ulcerative colitis who presented with epistaxis 1 week after receiving the first induction dose of vedolizumab found to have a severe immune-mediated thrombocytopenia and hemolytic anemia, otherwise known as Evan's syndrome. Wolters Kluwer 2019-02-13 /pmc/articles/PMC6657984/ /pubmed/31598531 http://dx.doi.org/10.14309/crj.0000000000000002 Text en © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Jen, Henry
Morganstern, Bradley
D'Souza, Lionel
A Case of Evan's Syndrome Induced by Vedolizumab
title A Case of Evan's Syndrome Induced by Vedolizumab
title_full A Case of Evan's Syndrome Induced by Vedolizumab
title_fullStr A Case of Evan's Syndrome Induced by Vedolizumab
title_full_unstemmed A Case of Evan's Syndrome Induced by Vedolizumab
title_short A Case of Evan's Syndrome Induced by Vedolizumab
title_sort case of evan's syndrome induced by vedolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657984/
https://www.ncbi.nlm.nih.gov/pubmed/31598531
http://dx.doi.org/10.14309/crj.0000000000000002
work_keys_str_mv AT jenhenry acaseofevanssyndromeinducedbyvedolizumab
AT morgansternbradley acaseofevanssyndromeinducedbyvedolizumab
AT dsouzalionel acaseofevanssyndromeinducedbyvedolizumab
AT jenhenry caseofevanssyndromeinducedbyvedolizumab
AT morgansternbradley caseofevanssyndromeinducedbyvedolizumab
AT dsouzalionel caseofevanssyndromeinducedbyvedolizumab

Ejemplares similares